BBS-BIOACTIVE BONE SUBSTITUTES OYJ BBS-Bioactive Bone Substitutes Oyj Stock
Equities
BONEH
FI4000260583
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.335 EUR | -4.29% |
|
-14.32% | -31.49% |
| Sales 2024 * | - | Sales 2025 * | 600K 641K 878K | Capitalization | 6.46M 6.91M 9.46M |
|---|---|---|---|---|---|
| Net income 2024 * | -3M -3.21M -4.39M | Net income 2025 * | -4M -4.28M -5.86M | EV / Sales 2024 * | - |
| Net Debt 2024 * | 6.7M 7.16M 9.81M | Net Debt 2025 * | 11.5M 12.29M 16.84M | EV / Sales 2025 * | 29.9 x |
| P/E ratio 2024 * |
-1.97
x | P/E ratio 2025 * |
-1.52
x | Employees | 20 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.47% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.29% | ||
| 1 week | -14.32% | ||
| Current month | -7.46% | ||
| 1 month | -13.66% | ||
| 3 months | -30.35% | ||
| 6 months | -30.06% | ||
| Current year | -31.49% |
1 week
0.27
0.40
1 month
0.270.49
Current year
0.270.66
1 year
0.270.86
3 years
0.273.59
5 years
0.2714.10
10 years
0.2714.10
| Managers | Title | Age | Since |
|---|---|---|---|
Juliusz Rakowski
CEO | Chief Executive Officer | - | 11-02 |
| Founder | 83 | 02-12-31 | |
Jari Kortesluoma
DFI | Director of Finance/CFO | - | 22-10-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 15-12-31 | |
| Director/Board Member | - | 20-08-16 | |
| Founder | 83 | 02-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-20 | 0.335 | -4.29% | 14,426 |
| 24-06-19 | 0.35 | +14.01% | 37,980 |
| 24-06-18 | 0.307 | -22.67% | 121,868 |
| 24-06-17 | 0.397 | +1.53% | 21,894 |
| 24-06-14 | 0.391 | -5.56% | 19,292 |
Delayed Quote Nasdaq Helsinki, June 20, 2024 at 12:00 pm
More quotes
BBS-Bioactive Bone Substitutes Oyj (BBS) is a Finland-based company engaged in the medical equipment industry. The Company operates as a biotechnology company that develops and distributes medical device implants used in orthopedic surgery. Its products include ARTEBONE, an orthopedic bone substitute material made from reindeer bone protein matrix made using a propriety patented manufacturing process that can be used in various application areas, such as bone regeneration, healing of fractures, non-unions, bone defect, dental implantation, orthopedics, maxillofacial/dental surgery and osteoporotic fractures.
Calendar
2024-08-29
- Q2 2024 Earnings Release
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
1
Last Close Price
0.335
EUR
Average target price
0.4
EUR
Spread / Average Target
+19.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -31.49% | 6.91M | |
| +14.42% | 131B | |
| -15.80% | 7.33B | |
| +42.18% | 5.69B | |
| -20.14% | 4.83B | |
| +8.58% | 3.45B | |
| -19.51% | 2.47B | |
| -17.70% | 1.93B | |
| -19.46% | 1.79B | |
| -34.15% | 1.52B |
- Stock Market
- Equities
- BONEH Stock
